Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Enrolling by invitation 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1Genitourinary 1

Conditions

Lymphoma, Non-Hodgkin 3Leukemia, Lymphocytic, Chronic, B-Cell 3Prostatic Neoplasms, Castration-Resistant 1Neoplasms 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1

Interventions

enzalutamide 10Prednisone 6Docetaxel 5Abiraterone Acetate 4darolutamide 3olaparib 2niraparib 2abiraterone 2Pluvicto 2zimberelimab 1xentuzumab 1sacituzumab govitecan 1radium Ra 223 dichloride 1quemliclustat 1ibrutinib 1gedatolisib 1gallium 68 PSMA-11 1fludrocortisone acetate 1cabazitaxel 1TVB-2640 1Rosuvastatin Calcium 1Pioglitazone 1Omeprazole 1Nivolumab 1JNJ-64619178 1JNJ-64264681 1Ipilimumab 1Gonadotropin-Releasing Hormone 1Dexamethasone 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostatic Neoplasms, Castration-Resistant × JNJ-64264681 × 1 year × Clear all
NCT06788509 2026-06-05

A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring

Janssen Research & Development, LLC

Phase 1 Enrolling by invitation
120 enrolled
GenitourinaryLymphoidMyeloidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡